Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Treatment of Hairy Cell Leukemia in its Second Half-Century

Monday, April 26, 2010 - Tuesday, April 27, 2010
Wilson Hall (Building 1), 3rd floor, Bethesda, MD

Goals of this conference were to (1) disseminate current knowledge of the standard treatment of hairy cell leukemia (HCL); (2) identify the evidence (or lack thereof) on which current treatment practices are based; (3) determine needs and opportunities for clinical research to improve HCL treatment; (4) disseminate results of newer diagnostic techniques, including flow cytometry, polymerase chain reaction (PCR), and serum markers, to allow decreased reliance on bone marrow biopsy; (5) discuss recent advances in HCL biology, including the molecular characterization of HCL cells with implications for disease origination/prognosis; (6) discuss new treatments for relapse/refractory disease, including investigational agents; (7) improve patient access to treatment and clinical trials; and (8) discuss the evolving activities of the HCL Consortium, including establishing a new HCL Web site to improve access to knowledge, care givers, treatment, and clinical trials. For additional information please contact Dr. Robert Kreitman at

Dr. Robert Kreitman, 301-496-6947

Co-funding Institute(s):
National Cancer Institute
Office of Rare Diseases Research

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.